{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:44:21Z","timestamp":1789083861760,"version":"build-2803163510"},"reference-count":4,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,10]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We present 5-year survival results in patients with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL) from TRANSCEND NHL 001 (TRANSCEND), including data from the separate long-term follow-up (LTFU) study. Overall, 345 patients were leukapheresed and 270 received lisocabtagene maraleucel (liso-cel). Among 257 patients who were efficacy-evaluable, median overall survival (OS) was 27.5 months (95% confidence interval [CI], 16.2-47.3; leukapheresed set: 15.2 months; 95% CI, 11.5-23.4); estimated 5-year OS was 38% (95% CI, 32-45; leukapheresed set: 33%; 95% CI, 28-39). Median disease-specific survival (DSS; excludes deaths unrelated to disease progression) was 67.8 months (95% CI, 23.5 to not reached [NR]; leukapheresed set: 27.4 months; 95% CI, 14.4-69.7]); estimated 5-year DSS was 52% (95% CI, 45-59; leukapheresed set: 47%; 95% CI, 41-52). Among patients from TRANSCEND who were efficacy-evaluable, alive at study completion, and enrolled in the LTFU (n = 84), median OS and DSS were NR (95% CI, NR to NR); estimated 5-year OS and DSS were 78% (95% CI, 67-86) and 92% (95% CI, 84-97), respectively. Most deaths occurred \u22642 years after infusion; no new safety signals were observed with low rates of late severe infections and second primary malignancies. These data support the curative potential of liso-cel in patients with R\/R LBCL. This trial was registered at www.clinicaltrials.gov as NCT02631044 and NCT03435796.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032270","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:02:42Z","timestamp":1780556562000},"page":"1388-1393","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Five-year survival outcomes of lisocabtagene maraleucel in R\/R LBCL from the TRANSCEND NHL 001 study"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"first","affiliation":[{"name":"1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"2City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1666-7064","authenticated-orcid":false,"given":"Leo I.","family":"Gordon","sequence":"additional","affiliation":[{"name":"3Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"5The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Arnason","sequence":"additional","affiliation":[{"name":"6Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-152X","authenticated-orcid":false,"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"7University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"8Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"8Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Andreadis","sequence":"additional","affiliation":[{"name":"9Department of Medicine, University of California, San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Sehgal","sequence":"additional","affiliation":[{"name":"10University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[{"name":"11Northside Hospital Cancer Institute, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"12Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-5837","authenticated-orcid":false,"given":"Juliana E.","family":"Hidalgo-L\u00f3pez","sequence":"additional","affiliation":[{"name":"13Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"14Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Ding","sequence":"additional","affiliation":[{"name":"14Bristol Myers Squibb, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-8927","authenticated-orcid":false,"given":"Ken","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"13Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashvin","family":"Singh","sequence":"additional","affiliation":[{"name":"13Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"15Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10254","key":"2026091007221266900_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"2026091007221266900_bib2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"19","key":"2026091007221266900_bib3","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026091007221266900_bib4","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/11\/1388\/2588071\/blood_bld-2025-032270-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/11\/1388\/2588071\/blood_bld-2025-032270-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:22:24Z","timestamp":1789039344000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/11\/1388\/568859\/Five-year-survival-outcomes-of-lisocabtagene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":4,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032270","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,10]]},"published":{"date-parts":[[2026,9,10]]}}}